IRB-Brasil Resseguros Valuation
Is IRBR3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IRBR3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IRBR3 (R$39.44) is trading above our estimate of fair value (R$11.52)
Significantly Below Fair Value: IRBR3 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IRBR3?
Key metric: As IRBR3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is IRBR3's PE Ratio? | |
|---|---|
| PE Ratio | 6.2x |
| Earnings | R$517.75m |
| Market Cap | R$3.34b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | 3.6x |
| PEG Ratio | 0.4x |
Price to Earnings Ratio vs Peers
How does IRBR3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.4x | ||
WIZC3 Wiz Co Participações e Corretagem de Seguros | 5.1x | 5.2% | R$967.4m |
CSAB4 Companhia de Seguros Alianca da Bahia | 23.2x | n/a | R$305.2m |
PSSA3 Porto Seguro | 9x | 7.2% | R$24.5b |
A003690 Korean Reinsurance | 8.4x | 15.4% | ₩1.7t |
IRBR3 IRB-Brasil Resseguros | 6.2x | 15.5% | R$3.3b |
Price-To-Earnings vs Peers: IRBR3 is good value based on its Price-To-Earnings Ratio (6.2x) compared to the peer average (11.4x).
Price to Earnings Ratio vs Industry
How does IRBR3's PE Ratio compare vs other companies in the South American Insurance Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: IRBR3 is good value based on its Price-To-Earnings Ratio (6.2x) compared to the Global Insurance industry average (11.3x).
Price to Earnings Ratio vs Fair Ratio
What is IRBR3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 6.2x |
| Fair PE Ratio | 6.8x |
Price-To-Earnings vs Fair Ratio: IRBR3 is good value based on its Price-To-Earnings Ratio (6.2x) compared to the estimated Fair Price-To-Earnings Ratio (6.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | R$39.44 | R$48.29 +22.4% | 9.9% | R$56.00 | R$43.00 | n/a | 7 |
| Nov ’25 | R$41.69 | R$48.71 +16.8% | 9.5% | R$56.00 | R$44.00 | n/a | 7 |
| Oct ’25 | R$44.81 | R$48.14 +7.4% | 11.0% | R$56.00 | R$41.00 | n/a | 7 |
| Sep ’25 | R$48.38 | R$47.83 -1.1% | 11.8% | R$56.00 | R$41.00 | n/a | 6 |
| Aug ’25 | R$28.93 | R$41.88 +44.7% | 7.3% | R$45.00 | R$37.00 | n/a | 6 |
| Jul ’25 | R$31.41 | R$43.87 +39.7% | 7.1% | R$48.10 | R$38.00 | n/a | 7 |
| Jun ’25 | R$31.56 | R$43.87 +39.0% | 7.1% | R$48.10 | R$38.00 | n/a | 7 |
| May ’25 | R$42.48 | R$44.16 +3.9% | 7.4% | R$48.10 | R$38.00 | n/a | 7 |
| Apr ’25 | R$38.26 | R$43.73 +14.3% | 7.0% | R$48.10 | R$38.00 | n/a | 7 |
| Mar ’25 | R$38.81 | R$43.73 +12.7% | 7.0% | R$48.10 | R$38.00 | n/a | 7 |
| Feb ’25 | R$40.35 | R$42.94 +6.4% | 8.3% | R$48.10 | R$38.00 | n/a | 7 |
| Jan ’25 | R$44.30 | R$41.59 -6.1% | 16.0% | R$51.00 | R$29.00 | n/a | 7 |
| Dec ’24 | R$53.63 | R$41.59 -22.5% | 16.0% | R$51.00 | R$29.00 | n/a | 7 |
| Nov ’24 | R$41.54 | R$39.03 -6.0% | 15.8% | R$51.00 | R$29.00 | R$41.69 | 7 |
| Oct ’24 | R$44.00 | R$39.03 -11.3% | 15.8% | R$51.00 | R$29.00 | R$44.81 | 7 |
| Sep ’24 | R$41.91 | R$38.24 -8.8% | 18.0% | R$51.00 | R$29.00 | R$48.38 | 7 |
| Aug ’24 | R$40.79 | R$35.67 -12.5% | 22.5% | R$51.00 | R$25.00 | R$28.93 | 7 |
| Jul ’24 | R$43.55 | R$35.67 -18.1% | 22.5% | R$51.00 | R$25.00 | R$31.41 | 7 |
| Jun ’24 | R$39.08 | R$31.24 -20.1% | 30.1% | R$51.00 | R$21.00 | R$31.56 | 7 |
| May ’24 | R$31.47 | R$33.57 +6.7% | 39.6% | R$57.00 | R$21.00 | R$42.48 | 7 |
| Apr ’24 | R$22.24 | R$37.00 +66.4% | 33.1% | R$57.00 | R$24.00 | R$38.26 | 7 |
| Mar ’24 | R$18.93 | R$37.29 +97.0% | 32.1% | R$57.00 | R$24.00 | R$38.81 | 7 |
| Feb ’24 | R$25.30 | R$37.29 +47.4% | 32.1% | R$57.00 | R$24.00 | R$40.35 | 7 |
| Jan ’24 | R$25.80 | R$38.14 +47.8% | 31.1% | R$57.00 | R$24.00 | R$44.30 | 7 |
| Dec ’23 | R$21.00 | R$53.50 +154.8% | 44.6% | R$100.50 | R$27.00 | R$53.63 | 9 |
| Nov ’23 | R$30.00 | R$57.83 +92.8% | 44.6% | R$100.50 | R$33.00 | R$41.54 | 9 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Globe Life
US$9.4b
Through its subsidiaries, provides various life and supplemental health insurance products, and annuities to lower middle- and middle-income families in the United States.
G1LL34
US$31.91
7D
1.6%
1Y
10.3%
Aegon
€9.6b
Provides insurance, pensions, retirement, and asset management services in the United States, the Netherlands, the United Kingdom, and internationally.
A1EG34
€37.27
7D
3.0%
1Y
38.2%